文献速递药物不良反应与药物警戒抗栓抗凝管理

血清素能抗抑郁药与左心室辅助装置患者出血风险的关联

Association of bleeding with serotonergic antidepressants in patients receiving left ventricular assist device support.
PubMed 文献 · Pharmacotherapy · 2021-10-25

单中心回顾性队列研究纳入连续接受CF-LVAD植入且术后存活≥30天的成人患者,比较使用与未使用血清素能抗抑郁药(SA)者从术后30天至18个月的出血情况。SA组首次出血事件发生率高于对照组,校正混杂因素后SA使用仍与出血相关。

要点

  • CF-LVAD患者使用SA与首次出血事件风险升高相关
  • 出血风险升高主要由胃肠道出血驱动
  • HeartMate 3患者出血风险低于HeartMate II患者

核心结论

  • 在接受CF-LVAD支持的患者中,SA使用与首次出血事件发生率相关,且主要由胃肠道出血驱动。
  • 需进一步研究评估不同SA药物间出血风险差异及调整抗栓策略的价值。

研究设计与样本

  • 纳入年龄≥18岁、植入HVAD、HeartMate II或HeartMate 3且术后存活至少30天的患者。

主要发现

  • 随访期间共219例发生出血事件:SA组93/203(45.8%),对照组126/391(32.2%),p=0.001。
  • 校正年龄、ACE抑制剂/ARB使用、出血史、吸烟史和CF-LVAD类型后,SA使用仍与出血相关(校正OR 1.75,95%CI 1.22-2.51,p=0.002)。
  • HeartMate 3患者出血少于HeartMate II患者(校正OR 0.46,95%CI 0.23-0.90,p=0.024)。

临床怎么用

  • 对接受CF-LVAD支持的患者启动SA时应评估出血风险并加强监测。
  • 尤其关注胃肠道出血风险,结合器械类型(HeartMate 3与HeartMate II)综合评估。

局限性

  • 为单中心回顾性队列研究。
  • 原文未报告SA药物间差异及调整抗栓策略的效果,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: This study sought to determine whether SA use is associated with bleeding in patients receiving CF-LVAD support. DESIGN: A retrospective cohort analysis was conducted of all adult patients who received CF-LVAD implantation at our institution. SETTING: Barnes-Jewish Hospital between July 1, 2009, and October 1, 2018. PATIENTS: Patients at least 18 years of age who received a HVAD™ (HeartWare Corp.), HeartMate II™ (St. Jude Medical), or HeartMate 3™ (St. Jude Medical) CF-LVAD and survived for at least 30 days postoperatively were included. INTERVENTION: Patients who received SAs (n = 203) were compared to those who did not (n = 391) from 30 days to 18 months following implantation. The primary outcome was the incidence of first bleeding events including gastrointestinal bleed (GIB), epistaxis, or intracerebral hemorrhage (ICH). MEASUREMENTS AND MAIN RESULTS: During follow-up, 219 patients had bleeding events: 93 of 203 (45.8%) in the SA group versus 126 of 391 (32.2%) in the control group (p = 0.001). After adjustment for age, angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) use, history of bleeding events, history of smoking, and CF-LVAD type, SA use remained associated with bleeding (adjusted odds ratio: 1.75, 95% confidence interval: 1.22-2.51, p = 0.002). HeartMate 3™ patients experienced less bleeding than HeartMate II™ patients (adjusted odds ratio 0.46, 95% confidence interval: 0.23-0.90, p = 0.024). CONCLUSIONS: In this single-center, retrospective cohort of patients supported with CF-LVADs, SA use was associated with the incidence of first bleeding events, primarily driven by GIB. Further studies are needed to assess any differential risk of bleeding among SA agents and to assess the utility of altering antithrombotic strategies.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Robinson AC, January SE, Botkin KW, et al. Association of bleeding with serotonergic antidepressants in patients receiving left ventricular assist device support. Pharmacotherapy. 2021. PMID: 34655495. doi:10.1002/phar.2632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。